I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

Table 1 Characteristics of the included studies

Study/year/country	Study design	Cancer types	Stage	Groups	Sample size	Age (years)	M/F	NOS
Luo/2013/China [11]	RCT	A; SC	III	Chemotherapy alone	17	48–72 for all	18/16 for all	–
Luo/2013/China [11]	RCT	A; SC	III	Combined	17	48–72 for all	18/16 for all	–
Xiang/2015/China [12]	Retrospective	A; SC; other	III, IV	Chemotherapy alone	41	56.8	30/11	8
Xiang/2015/China [12]	Retrospective	A; SC; other	III, IV	Combined	37	59.5	25/12	8
Xiang/2021/China [13]	Retrospective	A; SC; other	III, IV	Chemotherapy alone	94	55.4	71/23	8
Xiang/2021/China [13]	Retrospective	A; SC; other	III, IV	Combined	116	58.5	81/35	8
Yu/2015/China [14]	RCT	A; SC; other	III	Chemotherapy alone	26	62	15/11	–
Yu/2015/China [14]	RCT	A; SC; other	III	Combined	26	62	17/9	–
Zhang/2014/China [15]	Retrospective	A; SC; other	III, IV	Chemotherapy alone	35	54	28/7	8
Zhang/2014/China [15]	Retrospective	A; SC; other	III, IV	Combined	34	52	25/9	8
Zheng/2020/China [16]	Retrospective	A; SC; other	III, IV	Chemotherapy alone	44	46–70	31/13	8
Zheng/2020/China [16]	Retrospective	A; SC; other	III, IV	Combined	42	45–70	25/17	8

NOS Newcastle–Ottawa scale, RCT randomized controlled trial, SC squamous carcinoma; A adenocarcinoma, M male, F female

ISSN: 1749-8090